Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 5/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10090009 | 0.93 | MMP13 (0.38) | MMP13DHODHCNR1CNR2LMNA | |
| SCHEMBL10089880 | 0.93 | PTGER4 (0.35) | HDAC6IDH1DHODHEGLN1LMNA | |
| SCHEMBL10090049 | 0.91 | MEN1 (0.36) | DHODHCNR2PPARGLMNA | |
| SCHEMBL10090018 | 0.90 | IDH1 (0.36) | MMP13HDAC6IDH1DHODHEGLN1 | |
| SCHEMBL10089964 | 0.89 | RIPK1 (0.37) | PPARG | |
| SCHEMBL10089958 | 0.89 | DHODH (0.38) | MMP13HDAC6IDH1DHODHEGLN1 | |
| SCHEMBL10090040 | 0.88 | EGLN1 (0.36) | MMP13IDH1DHODHEGLN1CNR2 | |
| SCHEMBL15905592 | 0.87 | DHODH (0.37) | MMP13IDH1DHODHEGLN1CNR1 | |
| SCHEMBL10089899 | 0.87 | HSD17B13 (0.40) | DHODH | |
| SCHEMBL10089892 | 0.86 | DHODH (0.38) | MMP13HDAC6IDH1DHODHCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582695-B1 | ANTHRANILIC ACID DIAMIDE DERIVATIVES WITH CYCLICAL SIDE CHAINS | BAYER IP GMBH (DE) | 2015-09-30 | — | — | EP | disclosed |
| US-8791143-B2 | Anthranilic diamide derivatives having cyclic side-chains | BAYER CROPSCIENCE AG (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120010249-A1 | Anthranilic diamide derivatives having cyclic side-chains | BAYER CROPSCIENCE AG (DE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010249-A1 | Anthranilic diamide derivatives having cyclic side-chains | DDT, ADCY1, ANTXR2 | MMP13 4356/4885HDAC6 692/4885IDH1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.